<List><item><source>MED</source><extId>25170270</extId><pmcid>PMC4144843</pmcid><annotations><annotation><prefix>d the IMPACT trial (</prefix><exact>NCT00065442</exact><postfix>), which definitivel</postfix><tags><tag><name>NCT00065442</name><uri>http://identifiers.org/clinicaltrials/NCT00065442</uri></tag></tags><id>http://europepmc.org/articles/PMC4144843#europepmc-ea8a4aa392f6c905ece2bd4d3f14a750</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>sitive prostate cancer (PROTECT), via </prefix><exact>NCT00779402</exact><postfix>. </postfix><tags><tag><name>NCT00779402</name><uri>http://identifiers.org/clinicaltrials/NCT00779402</uri></tag></tags><id>http://europepmc.org/articles/PMC4144843#europepmc-fd850dd77f4315a568fa8e7490ba9dcc</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> a Phase III trial (</prefix><exact>NCT00417079</exact><postfix>) conducted in 755 p</postfix><tags><tag><name>NCT00417079</name><uri>http://identifiers.org/clinicaltrials/NCT00417079</uri></tag></tags><id>http://europepmc.org/articles/PMC4144843#europepmc-2520af3661ca53293b18f8f85698d9d6</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>III ALSYMPCA study (</prefix><exact>NCT00699751</exact><postfix>) which evaluated 92</postfix><tags><tag><name>NCT00699751</name><uri>http://identifiers.org/clinicaltrials/NCT00699751</uri></tag></tags><id>http://europepmc.org/articles/PMC4144843#europepmc-281ec37ece7a00998bb93f2a93358bed</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>